Introduction and Overview of RSV and Nirsevimab
Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, introduce the objectives of their discussion and background information on Respiratory Syncytial Virus (RSV) and nirsevimab.
Transcript
Tina Tan, MD, FAAP, FIDSA, FPIDS: Hello, and welcome to Between the Lines, a Journal Club experience. Today’s featured article is “Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.” This was published in the New England Journal of Medicine, the March 3, 2022, issue. My name is Dr Tina Tan. I’m a professor of pediatrics at the Feinberg School of Medicine of Northwestern University and a pediatric infectious disease physician, medical director of the International Patient and Destination Services Program, and vice president of the Lurie Medical Dental Staff at Ann and Robert H. Lurie Children’s Hospital of Chicago in Illinois. I’m also vice president of the board of directors of the Infectious Diseases Society of America. Joining me today is Dr Flora Munoz. She’s an associate professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine and medical director of the Transplant Infectious Disease Service at Texas Children’s Hospital, both in Houston, Texas. Welcome, [Dr Munoz]. This is going to be great. In today’s discussion, we’re going to be reviewing the data from a phase 3 trial examining the efficacy and safety of nirsevimab in healthy late-preterm and term infants beginning their first viral season. When you think about RSV, we know that RSV is a major cause of lower respiratory tract infection and hospitalization, especially in healthy term infants. However, the interventions available for treatment currently are lacking to combat this virus. Previous investigation of nirsevimab, a monoclonal antibody to the RSV fusion protein, demonstrated favorable benefits when administered to healthy preterm infants prior to the RSV season. And as such, a further investigation was completed to examine the efficacy and safety of nirsevimab and healthy late-preterm and term infants starting their first RSV season.
Transcript was AI-generated and edited for clarity.
